Can People With Blood Cancer Receive Fully Protection Against Covid 19 After Mrna Vaccines Studies

Speculation about the impact and safety of the special Kovid-19 vaccine has been hot in the market, especially for those struggling with a marked health condition. Some experts say that people with certain types of allergies should avoid getting vaccinated, the other puts such cancer patients at greater risk. Meanwhile, the world is seeing an unprecedented surge in cases of Kovid-19, in such a situation it is important to know how effective the Kovid-19 vaccine is for the cancer patients undergoing treatment.

 

Two dose mRNA vaccine less effective 

 

Taking a step towards discovery, researchers have found that particular vaccines may be less effective in people being treated for cancer. According to two research published in the journal Blood, both doses of mRNA-based covid vaccine may be less effective in people being treated for blood cancer. Based on the results, they reported that the mRNA covid-19 vaccine may not show efficacy in patients with chronic lymphocytic leukemia and multiple myeloma compared to healthy people.

 

Chronic lymphocytic leukemia is the most common type of leukemia that affects adults. This is a type of bone marrow and blood cancer. Multiple myeloma, on the other hand, is a cancer of plasma cells, a type of white cell that produces anti-bodies. However, researchers have clarified that vaccination against the corona virus is still important among these patients.

 

Cancer patients show low response rate

 

A Tel Aviv researcher in Israel says, “Even though the response may not be excessive, patients with chronic lymphocytic leukemia should still be vaccinated, if possible, before starting treatment, although the disease itself B can affect the response itself. ” Researchers screened 167 patients with chronic lymphocytic leukemia and 53 healthy patients.

 

Both groups were given both doses of Pfizer’s Kovid-19 vaccine. After analysis, he found that those who were undergoing treatment for cancer, found 16 percent of the immune response from the vaccine. The outcome of patients with chronic lymphocytic leukemia depended on their cancer treatment process. People with chronic lymphocytic leukemia who were being monitored but not receiving treatment showed a response rate of 55.5 percent.

 

In contrast, 94 percent of the immune response rate was found in those who completed their treatment a year before vaccination. Researchers reported that the response rate to the vaccine clearly appeared to be lower than in the general population, which accounted for the most likelihood of cancer and certainly chronic lymphocytic leukemia. He also said that patients with chronic lymphocytic leukemi had lower anti-body as well, which meant that the intensity of response was low.

LEAVE A REPLY

Please enter your comment!
Please enter your name here